JP2022513666A5 - - Google Patents
Info
- Publication number
- JP2022513666A5 JP2022513666A5 JP2021530872A JP2021530872A JP2022513666A5 JP 2022513666 A5 JP2022513666 A5 JP 2022513666A5 JP 2021530872 A JP2021530872 A JP 2021530872A JP 2021530872 A JP2021530872 A JP 2021530872A JP 2022513666 A5 JP2022513666 A5 JP 2022513666A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- ibrutinib
- composition according
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773678P | 2018-11-30 | 2018-11-30 | |
| US62/773,678 | 2018-11-30 | ||
| PCT/US2019/063234 WO2020112761A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating follicular lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513666A JP2022513666A (ja) | 2022-02-09 |
| JP2022513666A5 true JP2022513666A5 (https=) | 2022-11-18 |
Family
ID=68966021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530872A Ceased JP2022513666A (ja) | 2018-11-30 | 2019-11-26 | 濾胞性リンパ腫の治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200171034A1 (https=) |
| EP (1) | EP3886992A1 (https=) |
| JP (1) | JP2022513666A (https=) |
| KR (1) | KR20210097160A (https=) |
| CN (1) | CN113164782A (https=) |
| AU (1) | AU2019388899A1 (https=) |
| BR (1) | BR112021009978A2 (https=) |
| CA (1) | CA3120960A1 (https=) |
| EA (1) | EA202191509A1 (https=) |
| IL (1) | IL283365A (https=) |
| JO (1) | JOP20210126A1 (https=) |
| MA (1) | MA54292A (https=) |
| MX (1) | MX2021006368A (https=) |
| PH (1) | PH12021551140A1 (https=) |
| SG (1) | SG11202105309YA (https=) |
| WO (1) | WO2020112761A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| CA2914284A1 (en) * | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20160032404A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| CA2980393A1 (en) * | 2015-03-18 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Methods for diagnosing and treating follicular lymphoma |
| HK1250925A1 (zh) * | 2015-04-06 | 2019-01-18 | Janssen Pharmaceutica, N.V. | 包含依鲁替尼的组合物 |
| WO2017087947A2 (en) * | 2015-11-19 | 2017-05-26 | Pharmacyclics Llc | Method of treatment of follicular lymphoma with a btk inhibitor |
| PH12021551936A1 (en) * | 2019-02-15 | 2022-05-23 | Janssen Biotech Inc | Combination therapy for treatment of b-cell malignancies |
-
2019
- 2019-11-26 EP EP19824085.5A patent/EP3886992A1/en not_active Withdrawn
- 2019-11-26 EA EA202191509A patent/EA202191509A1/ru unknown
- 2019-11-26 MX MX2021006368A patent/MX2021006368A/es unknown
- 2019-11-26 CA CA3120960A patent/CA3120960A1/en active Pending
- 2019-11-26 SG SG11202105309YA patent/SG11202105309YA/en unknown
- 2019-11-26 KR KR1020217020004A patent/KR20210097160A/ko not_active Withdrawn
- 2019-11-26 US US16/696,092 patent/US20200171034A1/en not_active Abandoned
- 2019-11-26 JO JOP/2021/0126A patent/JOP20210126A1/ar unknown
- 2019-11-26 AU AU2019388899A patent/AU2019388899A1/en not_active Abandoned
- 2019-11-26 BR BR112021009978-6A patent/BR112021009978A2/pt not_active IP Right Cessation
- 2019-11-26 WO PCT/US2019/063234 patent/WO2020112761A1/en not_active Ceased
- 2019-11-26 JP JP2021530872A patent/JP2022513666A/ja not_active Ceased
- 2019-11-26 CN CN201980078851.9A patent/CN113164782A/zh active Pending
- 2019-11-26 MA MA054292A patent/MA54292A/fr unknown
-
2021
- 2021-05-19 PH PH12021551140A patent/PH12021551140A1/en unknown
- 2021-05-23 IL IL283365A patent/IL283365A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Purcell et al. | LRRC15 is a novel mesenchymal protein and stromal target for antibody–drug conjugates | |
| Slingerland et al. | Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors | |
| KR20240056564A (ko) | T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도 | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| JP2017048208A5 (https=) | ||
| Khan et al. | Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | |
| JP2016513640A5 (https=) | ||
| JP2021527092A5 (https=) | ||
| JP2016518387A5 (https=) | ||
| JP2023508496A5 (https=) | ||
| JP2020525435A5 (https=) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018522045A5 (https=) | ||
| JP2014525465A5 (https=) | ||
| JP2021513536A5 (https=) | ||
| JP2024527109A5 (https=) | ||
| JP2017533220A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| JP2022523530A5 (https=) | ||
| Wang et al. | Radiation therapy regulates TCF-1 to maintain CD8+ T cell stemness and promotes anti-tumor immunotherapy | |
| JP2018516936A5 (https=) | ||
| JP2018529766A5 (https=) | ||
| JP2024016209A5 (https=) | ||
| JP2022501332A5 (https=) | ||
| JP2022502508A5 (https=) |